🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

19 recruiting trials

for ER+, HER 2- Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer NCT06062498Phase 23 sites📍 Chicago📍 Chicago📍 Chicago Northwestern University · Tests: elacestrant, palbociclib, abemaciclib, ribociclib A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer NCT04872166Phase 16 sites📍 Lake Mary📍 Sarasota📍 Cincinnati Edgewood Oncology Inc. · Tests: BTX-A51 Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites📍 Phoenix📍 Irvine📍 San Diego RayzeBio, Inc. · Tests: RYZ101, Standard of Care Endocrine Therapy NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline NCT06452394Phase 28 sites📍 Sankt Gallen📍 Genolier📍 Winterthur Swiss Cancer Institute · Tests: Doxycyclin A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) NCT07541079Phase 38 sites📍 Fountain Valley📍 Stockton📍 Washington D.C. Genentech, Inc. · Tests: Giredestrant S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer NCT03723928NA723 sites📍 Anchorage📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Ques… Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy NCT02945579NA8 sites📍 Gilbert📍 Jacksonville📍 Honolulu M.D. Anderson Cancer Center · Tests: Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast I… Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer NCT07427394Phase 26 sites📍 St Louis📍 East Providence📍 Nashville AstraZeneca · Tests: Camizestrant, Atirmociclib Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast) NCT06925984NA5 sites📍 Brussels📍 Ghent📍 Kortrijk Jules Bordet Institute · Tests: SBRT Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC NCT06500208Phase 21 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer NCT06666439n/a1 site📍 Pittsburgh Julia Foldi · Tests: circulating tumor DNA (ctDNA) A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer NCT05187832Phase 11 site📍 Nashville Kind Pharmaceuticals LLC · Tests: AND019 PO QD A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors NCT07540572Phase 111 sites📍 Plantation📍 East Brunswick📍 Lake Success IDEAYA Biosciences · Tests: IDE574, Fulvestrant injection A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery NCT06127979NA1 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: blood draw Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer NCT06964906Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: HIFU, Toripalimab, nab-Paclitaxel (nab-P), Epirubicin (E), Cyclophosphamide (C) TCb vs EC-T in High Risk ER+/HER2- Breast Cancer NCT05901428Phase 31 site📍 Shanghai Fudan University · Tests: Docetaxel, Carboplatin, Epirubicin, Cyclophosphamide PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) NCT07222215Phase 21 site📍 Boston Kristina A. Fanucci · Tests: Capecitabine, Elacestrant A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer NCT07287098Phase 287 sites📍 Birmingham📍 Chandler📍 Phoenix Eli Lilly and Company · Tests: Imlunestrant, Goserelin, Tamoxifen 20 mg
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy